{
  "name" : "dacemirror.sci-hub.se_journal-article_e9e6104430848b9147ce724de14dff37_yoshinaga2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Bundling mRNA Strands to Prepare Nano-Assemblies with Enhanced Stability Towards RNase for In Vivo Delivery",
    "authors" : [ "Naoto Yoshinaga", "Eol Cho", "Kyoko Koji", "Yuki Mochida", "Mitsuru Naito", "Kensuke Osada", "Kazunori Kataoka", "Horacio Cabral", "Satoshi Uchida" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "In vitro-transcribed mRNA is a promising therapeutic option for various diseases.[1] However, the susceptibility of mRNA to ribonuclease (RNase)-mediated degradation in physiological environments is a major obstacle to the widespread in vivo application of mRNA. Approaches that have been taken to overcome this issue include the complexation of mRNA with cationic polymers, peptides or lipids,[2] and the chemical modification of mRNA nucleosides.[3] Nevertheless,\nmRNA degradation still poses a great challenge to the delivery of mRNA to target tissues in an intact form.\nHerein, we tackled this issue by proposing a novel strategy for protecting mRNA based on the formation of highly structured mRNA nano-assemblies (R-NAs). Studies in the growing field of RNA nanotechnology have shown that structured RNA presents enhanced RNase stability probably through steric hinderance to RNase attack, providing an effective delivery platform, for example, for small interference RNA (siRNA) delivery.[4] However, it is not trivial to use this approach for mRNA delivery. While the precise design of RNA sequence is required to provide intended base-pairing in the preparation of structured RNA, sequence flexibility is extremely low in mRNA compared to that of other applications of RNA nanotechnology. Furthermore, mRNA has a fixed structure containing a 5’-cap, 5’- and 3’-untranslated regions, a coding region, and a poly-A tail, and all these components play a critical role in protein translation and intracellular mRNA metabolism.[1] Therefore, to prepare structured mRNA, possessing all of these endogenous mRNA components without sequence optimization, we bundled mRNA strands by hybridizing RNA oligonucleotide linkers to prepare R-NAs (Figure 1). This simple approach of mRNA engineering boosted the RNase stability of mRNA by around 100-fold. Notably, the translational activity of R-NAs was maintained at a level comparable to na ve mRNA, presumably due to selective R-NA dissociation in the intracellular environment through an endogenous mRNA unwinding mechanism triggered by 5’-cap-dependent translation. As a result, R-NAs achieved efficient mRNA transfection to the mouse brain, demonstrating in vivo feasibility.\n[*] Dr. N. Yoshinaga,[+] E. Cho,[+] K. Koji,[+] Prof. Dr. H. Cabral, Prof. Dr. S. Uchida Graduate School of Engineering, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656 (Japan) E-mail: horacio@bmw.t.u-tokyo.ac.jp\nsuchida@bmw.t.u-tokyo.ac.jp\nDr. Y. Mochida, Prof. Dr. K. Kataoka, Prof. Dr. S. Uchida Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821 (Japan)\nDr. M. Naito Graduate School of Medicine, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 (Japan)\nDr. K. Osada National Institute of Radiological Science 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555 (Japan)\nProf. Dr. K. Kataoka Policy Alternatives Research Institute, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 (Japan)\n[+] These authors contributed equally to this work.\nSupporting information and the ORCID identification number(s) for the author(s) of this article can be found under: https://doi.org/10.1002/anie.201905203.\nFor crosslinking mRNA, RNA linkers were designed to contain two RNA arms, which are complementary to mRNA, on both sides, connected by a flexible chain comprised of a 10 nt oligoadenine RNA (Figure 2a). If the two arms on the\nsides hybridized to different positions in mRNA, the linkers would connect these two positions in the same mRNA strand. To avoid such linking within a single mRNA strand, we used the same sequences in the two complementary arms on the sides of the linkers. Moreover, in our previous mRNAengineering studies, we observed that the hybridization of mRNA with long RNA oligonucleotides led to decreased mRNA translational activity and increased mRNA immunogenicity, and that these undesirable responses after the formation of double stranded RNA (dsRNA) were avoided by limiting the hybridization length to 17 nt.[5] Therefore, we limited the length of the complementary arms of RNA linkers to 17 nt.\nTo prepare R-NAs, mRNA and the linkers were mixed by controlling the molar ratio of complementary arms in the linkers to mRNA to be 1. As a control, we prepared mRNA hybridized with non-linker RNA oligonucleotides (NL), comprised of a 17 nt sequence complementary to mRNA and 5 nt adenine RNA, at a NL to mRNA molar ratio of 1 (Figure 2 b). In the mRNA obtained (R-NL), the amount of\nadditional RNA hybridized to mRNA is the same as that in RNAs, without crosslinking between mRNA strands. It is worth noting that the mRNA remained intact after the hybridization process of heating and gradual cooling (Supporting Information, Figure S1).\nLuciferase (Luc) mRNA was hybridized with 2–8 RNA linkers, which target widely distributed positions in the mRNA (Supporting Information, Figure S2). The bundling state of mRNA strands was first evaluated by measuring the change in diffusion coefficient (D) of mRNA labeled with Cy5 using fluorescence correlation spectroscopy (FCS). D values decreased with the increase in the number of linkers, eventually to less than 50% of the initial value after hybridization of 6 or more linkers, while R-NL failed to show such a decrease in D values (Figure 2c). These results suggest that several mRNA strands bundle through RNA linkers to form R-NAs with an increased size. D values remained unchanged upon increasing linker number from 6 to 8. Thus, we used 8 linkers in the following experiments. FCS measurement further revealed that each R-NA was comprised of 7.7 mRNA strands on average (Data Set S1 in the Supporting Information). Atomic force microscopy (AFM) and dynamic light scattering demonstrated the successful preparation of RNAs with of several tens of nanometers in diameter after linker hybridization (Figure 2d–g and Supporting Information, Figure S3 and Table S1).\nThe stability of the R-NAs towards RNase was evaluated after incubation in fetal bovine serum (FBS). Intactness of mRNA after incubation was measured using quantitative real-time PCR (qRT-PCR), which amplifies RNA possessing an intact sequence between the primer pair. R-NAs required around 500-fold higher concentration of FBS than na ve mRNA to reduce the detected mRNA amount by 10% (Figure 3a). Compared to R-NL, which improved the stability of mRNA towards RNase to some extent, R-NAs required more than 40-fold higher FBS concentration to degrade 10% of mRNA. As the amount of dsRNA component is a possible determinant of stability towards RNase, we quantified it by using ethidium bromide (EtBr), which emits strong fluorescence after binding to dsRNA. The fluorescence intensity of R-NAs treated with EtBr increased with the number of RNA linkers, though the extent of the increase was almost comparable to that observed in R-NL (Figure 3b). Therefore,\n2 www.angewandte.org 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019, 58, 1 – 5\nThese are not the final page numbers!\nbecause R-NAs showed much higher stability towards RNase than R-NL (Figure 2), the stability enhancement of R-NAs cannot be solely explained by the increase in secondary RNA structure. Another plausible mechanism is the formation of higher order structures in R-NAs contributing to mRNA stabilization by steric hindrance of substrate RNA recognition by RNases, as reported for RNA nanotechnology.[4] On the other hand, the modest improvement in stability towards RNase observed when using R-NL compared to na ve mRNA may be mainly attributed to the increase in dsRNA amount. Notably, R-NAs of several tens of nanometers in diameter were also successfully prepared from green fluorescence protein (GFP) mRNA (Supporting Information, Figures S2 and S4, and Table S1), and the R-NAs from GFP mRNA exhibited significantly enhanced stability towards RNase compared to na ve mRNA (Supporting Information, Figure S5), demonstrating the versatility of our approach for the stabilization of other types of mRNA.\nThen, we evaluated the protein translational activity of RNAs. Luc expression level from R-NAs was comparable to that from na ve mRNA in a cell-free mRNA translation system from cell lysate (Figure 4a). In cultured cells, R-NAs\nyielded a comparable level of Luc expression after serum-free transfection, and higher level of expression after transfection in serum-containing medium, when compared to na ve mRNA (Supporting Information, Figures S6 and S7). RNAs from GFP mRNA also preserved their translational competency in cultured cells (Supporting Information, Figure S8). Intriguingly, our results indicate that R-NA was protected from RNase recognition (Figure 3 a), though the accessibility to the factors required for protein translation inside cells was preserved (Figure 4 a and Supporting Information, Figures S6–8). These apparently opposing results may be explained by the selective dissociation of R-NA in an intracellular environment. Indeed, cells have a dsRNA\nunwinding mechanism, such as the helicase activity of ribosomes during mRNA translation.[6] To gain an insight into the R-NA processing mechanism inside cells, we studied the relationship between translation and R-NA dissociation in cell lysates. Translational processes were controlled using uncapped mRNA, which showed less than 20 % of translational activity compared to that of capped mRNA,[7] and the R-NA dissociation was analyzed by measuring Fçrster resonance energy transfer (FRET) from Cy3-labeled RNA linkers to Cy5-labeled mRNA. FRET efficiency of R-NAs from capped mRNA decreased within 1 h of incubation in cell lysate, whereas that of R-NAs from uncapped mRNA remained constant after 4 h of incubation (Figure 4b). This result indicates that only R-NAs from capped mRNA dissociate in cell lysate. A plausible mechanism is that an initiation factor recognizes the 5’-cap in R-NAs to trigger translation, and the R-NAs are unwound during translation to facilitate further translation from the mRNA. Notably, RNAs from uncapped mRNA, which did not dissociate in cell lysate, exhibited significantly lower Luc expression in this condition, compare to na ve uncapped mRNA (Supporting Information, Figure S9), supporting our hypothesis that RNA dissociation contributes to mRNA translation.\nFinally, the applicability of our system for in vivo mRNA delivery was tested after Luc mRNA injection to the mouse brain without the use of delivery carriers. In qRT-PCR-based measurement of mRNA integrity in the brain, R-NA formulations increased the detected Luc mRNA amount in the brain by 17-fold 4 h after injection compared to na ve mRNA (Figure 5 a), indicating enhanced stability towards RNase in vivo. As a result, R-NAs showed a significantly higher level of Luc expression in the brain compared to na ve mRNA (Figure 5b). Notably, even without the use of delivery carriers, the Luc expression level of R-NAs reached one third of that from na ve mRNA delivered with a commonly used lipid-based transfection reagent. Avoiding the use of materials that do not exist naturally in the body, our system has safety advantages especially for targeting the brain, as waste clearance from the brain tends to be inefficient.[8] Furthermore, R-NAs induced the production of negligible levels of\n3Angew. Chem. Int. Ed. 2019, 58, 1 – 5 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org\nThese are not the final page numbers!\ninterferon-b (IFN-b) transcripts, a marker of the type I interferon response after dsRNA recognition (Supporting Information, Figure S10).[9] These results demonstrated the feasibility of R-NAs for in vivo mRNA administration in a safe and efficient manner.\nIn conclusion, we provided a boost in the stability of mRNA towards RNase to levels suitable for in vivo administration simply by bundling mRNA strands via RNA oligonucleotide linkers to prepare highly structured R-NAs. The diameter of R-NAs was mostly less than 100 nm, which is suitable for uptake by various types of cells and for obtaining desirable biodistribution after in vivo delivery.[10] The mRNA in R-NAs possesses all components of endogenous mRNA required for efficient translation, including a 5’-cap and a poly-A tail. Moreover, R-NAs preserved the protein translation activity comparable with na ve mRNA, presumably due to selective R-NA dissociation in the intracellular environment mediated by a 5’-cap-dependent translation, which triggers an endogenous mRNA unwinding mechanism. Although the assembly of protein-coding RNA can be also prepared by rolling circle transcription of plasmid DNA, a widely-used method for the preparation of structured RNA,[11] protein transcription in this approach relies on an internal ribosomal entry site, which tends to yield a much lower level of translational efficiency compared to capdependent translation.[12]\nOur approach provides an additional mRNA stabilization mechanism different to that of previous approaches, including mRNA complexation with cationic polymers/lipids, and mRNA chemical modification, and therefore, a synergistic effect could be expected to result from the combinational use of R-NAs with these existing approaches. Furthermore, the use of R-NAs alone without a cationic carrier also yielded efficient protein production in vivo. While naked mRNA is frequently used in clinical in vivo mRNA delivery,[13] our system has the potential to improve efficiency of mRNA delivery in such settings."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This research was financially supported by Grants-in-Aid for Scientific Research (B) [JP16H03179 to H.C., 18K03529 to S.U.], and Challenging Exploratory Research [JP18K19901 to H.C.] from the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT), Research and Development of Core Technologies for Gene and Cell Therapy [JP18ae0201009 to S.U.], and the Project for Cancer Research And Therapeutic Evolution (P-CREATE) [JP17cm0106202; H.C.] from Japan Agency for Medical Research and Development (AMED)."
    }, {
      "heading" : "Conflict of interest",
      "text" : "The authors declare no conflict of interest.\nKeywords: drug delivery · gene technology · mRNA · ribonuclease · RNA structure\n[1] U. Sahin, K. Kariko, O. Tureci, Nat. Rev. Drug Discovery 2014, 13, 759 – 780. [2] a) K. A. Hajj, K. A. Whitehead, Nat. Rev. Mater. 2017, 2, 17056; b) H. Cabral, K. Miyata, K. Osada, K. Kataoka, Chem. Rev. 2018, 118, 6844 – 6892. [3] a) B. R. Anderson, H. Muramatsu, B. K. Jha, R. H. Silverman, D. Weissman, K. Kariko, Nucleic Acids Res. 2011, 39, 9329 – 9338; b) S. Uchida, K. Kataoka, K. Itaka, Pharmaceutics 2015, 7, 137 – 151. [4] a) J. B. Lee, J. Hong, D. K. Bonner, Z. Poon, P. T. Hammond, Nat. Mater. 2012, 11, 316 – 322; b) C. Hao, X. Li, C. Tian, W. Jiang, G. Wang, C. Mao, Nat. Commun. 2014, 5, 3890. [5] a) S. Uchida, N. Yoshinaga, K. Yanagihara, E. Yuba, K. Kataoka, K. Itaka, Biomaterials 2018, 150, 162 – 170; b) N. Yoshinaga, S. Uchida, M. Naito, K. Osada, H. Cabral, K. Kataoka, Biomaterials 2019, 197, 255 – 267. [6] a) S. Rouskin, M. Zubradt, S. Washietl, M. Kellis, J. S. Weissman, Nature 2014, 505, 701 – 705; b) X. Qu, J. D. Wen, L. Lancaster, H. F. Noller, C. Bustamante, I. Tinoco, Jr., Nature 2011, 475, 118 – 121. [7] H. Uchida, K. Itaka, S. Uchida, T. Ishii, T. Suma, K. Miyata, M. Oba, N. Nishiyama, K. Kataoka, J. Am. Chem. Soc. 2016, 138, 1478 – 1481. [8] J. J. Iliff, M. Wang, Y. Liao, B. A. Plogg, W. Peng, G. A. Gundersen, H. Benveniste, G. E. Vates, R. Deane, S. A. Goldman, E. A. Nagelhus, M. Nedergaard, Sci. Transl. Med. 2012, 4, 147ra111.\n[9] T. Kawai, S. Akira, Nat. Immunol. 2010, 11, 373 – 384. [10] a) H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami,\nM. Kimura, Y. Terada, M. R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, K. Kataoka, Nat. Nanotechnol. 2011, 6, 815 – 823; b) N. Oh, J. H. Park, Int. J. Nanomed. 2014, 9 Suppl 1, 51 – 63. [11] H. Kim, Y. Park, J. B. Lee, Sci. Rep. 2015, 5, 12737. [12] H. Mizuguchi, Z. Xu, A. Ishii-Watabe, E. Uchida, T. Hayakawa,\nMol. Ther. 2000, 1, 376 – 382. [13] P. S. Kowalski, A. Rudra, L. Miao, D. G. Anderson, Mol. Ther.\n2019, 27, 710 – 728.\nManuscript received: April 26, 2019 Revised manuscript received: May 28, 2019 Accepted manuscript online: June 11, 2019 Version of record online: && &&, &&&&\n4 www.angewandte.org 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019, 58, 1 – 5\nThese are not the final page numbers!"
    }, {
      "heading" : "Communications",
      "text" : ""
    }, {
      "heading" : "RNA Nanotechnology",
      "text" : ""
    }, {
      "heading" : "N. Yoshinaga, E. Cho, K. Koji, Y. Mochida,",
      "text" : ""
    }, {
      "heading" : "M. Naito, K. Osada, K. Kataoka,",
      "text" : ""
    }, {
      "heading" : "H. Cabral,* S. Uchida* &&&&—&&&&",
      "text" : "Bundling mRNA Strands to Prepare Nano-Assemblies with Enhanced Stability Towards RNase for In Vivo Delivery\nmRNAs were bundled, through hybridization with RNA-oligonucleotide linkers, to form nano-assemblies (R-NAs), resulting in enhanced stability towards RNase and preserved translational activity. R-NAs could be delivered into mouse brain, without the use of a transfection reagent. This strategy could improve the efficiency of mRNA-based therapeutics.\n5Angew. Chem. Int. Ed. 2019, 58, 1 – 5 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org\nThese are not the final page numbers!"
    } ],
    "references" : [ {
      "title" : "Chem",
      "author" : [ "H. Uchida", "K. Itaka", "S. Uchida", "T. Ishii", "T. Suma", "K. Miyata", "M. Oba", "N. Nishiyama", "K. Kataoka", "J. Am" ],
      "venue" : "Soc. 2016, 138, 1478 –",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 1481
    }, {
      "title" : "Version of record",
      "author" : [ "P.S. Kowalski", "A. Rudra", "L. Miao", "D.G. Anderson", "Mol. Ther" ],
      "venue" : "Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019,",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2019
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Translational processes were controlled using uncapped mRNA, which showed less than 20 % of translational activity compared to that of capped mRNA,([7]) and the R-NA dissociation was analyzed by measuring Fçrster resonance energy transfer (FRET) from Cy3-labeled RNA linkers to Cy5-labeled mRNA.",
      "startOffset" : 148,
      "endOffset" : 151
    }, {
      "referenceID" : 1,
      "context" : "While naked mRNA is frequently used in clinical in vivo mRNA delivery,([13]) our system has the potential to improve efficiency of mRNA delivery in such settings.",
      "startOffset" : 71,
      "endOffset" : 75
    } ],
    "year" : 2019,
    "abstractText" : "Ribonuclease (RNase)-mediated degradation of messenger RNA (mRNA) poses a huge obstruction to in vivo mRNA delivery. Herein, we propose a novel strategy to protect mRNA by structuring mRNA to prevent RNase attack through steric hinderance. Bundling of mRNA strands through hybridization of RNA oligonucleotide linkers allowed the preparation of mRNA nano-assemblies (R-NAs) comprised of 7.7 mRNA strands on average, mostly below 100 nm in diameter. R-NA formation boosted RNase stability by around 100-fold compared to na ve mRNA and preserved translational activity, allowing protein production. A mechanistic analysis suggests that an endogenous mRNA unwinding mechanism triggered by 5’-cap-dependent translation may induce selective R-NA dissociation intracellularly, leading to smooth translation. R-NAs showed efficient mRNA transfection in mouse brain, demonstrating the feasibility for in vivo administration. In vitro-transcribed mRNA is a promising therapeutic option for various diseases. However, the susceptibility of mRNA to ribonuclease (RNase)-mediated degradation in physiological environments is a major obstacle to the widespread in vivo application of mRNA. Approaches that have been taken to overcome this issue include the complexation of mRNA with cationic polymers, peptides or lipids, and the chemical modification of mRNA nucleosides. Nevertheless, mRNA degradation still poses a great challenge to the delivery of mRNA to target tissues in an intact form. Herein, we tackled this issue by proposing a novel strategy for protecting mRNA based on the formation of highly structured mRNA nano-assemblies (R-NAs). Studies in the growing field of RNA nanotechnology have shown that structured RNA presents enhanced RNase stability probably through steric hinderance to RNase attack, providing an effective delivery platform, for example, for small interference RNA (siRNA) delivery. However, it is not trivial to use this approach for mRNA delivery. While the precise design of RNA sequence is required to provide intended base-pairing in the preparation of structured RNA, sequence flexibility is extremely low in mRNA compared to that of other applications of RNA nanotechnology. Furthermore, mRNA has a fixed structure containing a 5’-cap, 5’and 3’-untranslated regions, a coding region, and a poly-A tail, and all these components play a critical role in protein translation and intracellular mRNA metabolism. Therefore, to prepare structured mRNA, possessing all of these endogenous mRNA components without sequence optimization, we bundled mRNA strands by hybridizing RNA oligonucleotide linkers to prepare R-NAs (Figure 1). This simple approach of mRNA engineering boosted the RNase stability of mRNA by around 100-fold. Notably, the translational activity of R-NAs was maintained at a level comparable to na ve mRNA, presumably due to selective R-NA dissociation in the intracellular environment through an endogenous mRNA unwinding mechanism triggered by 5’-cap-dependent translation. As a result, R-NAs achieved efficient mRNA transfection to the mouse brain, demonstrating in vivo feasibility. Figure 1. Proposed strategy for mRNA delivery by bundling mRNA into nano-assemblies (R-NAs). [*] Dr. N. Yoshinaga, E. Cho, K. Koji, Prof. Dr. H. Cabral,",
    "creator" : "Arbortext Advanced Print Publisher 9.1.580/W"
  }
}